Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1026

1.
2.

Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163.

Standl E, Green JB, Holman RR; TECOS Study Group.

Diabetes Care. 2019 Jun;42(6):e95. doi: 10.2337/dc18-2597. No abstract available.

PMID:
31110121
3.

Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85).

Maddaloni E, Coleman RL, Pozzilli P, Holman RR.

Diabetes Obes Metab. 2019 Sep;21(9):2115-2122. doi: 10.1111/dom.13788. Epub 2019 Jun 19.

PMID:
31099472
4.

Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.

Guimarães PO, Peterson ED, Stevens SR, Lokhnygina Y, Green JB, McGuire DK, Holman RR, Lopes RD.

Int J Cardiol. 2019 Aug 15;289:58-62. doi: 10.1016/j.ijcard.2019.04.085. Epub 2019 Apr 30.

PMID:
31079973
5.

Insights into the Progression of Labile Hb A1c to Stable Hb A1c via a Mechanistic Assessment of 2,3-Bisphosphoglycerate Facilitation of the Slow Nonenzymatic Glycation Process.

Mottishaw CR, Becker S, Smith B, Titus G, Holman RW, Rodnick KJ.

Hemoglobin. 2019 Jan;43(1):42-49. doi: 10.1080/03630269.2019.1597731. Epub 2019 May 7.

PMID:
31060394
6.

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).

Bethel MA, Patel RA, Thompson VP, Merrill P, Reed SD, Li Y, Ahmadi S, Katona BG, Gustavson SM, Ohman P, Iqbal N, Gagel RF, Hernandez AF, Buse JB, Holman RR; EXSCEL Study Group.

Diabetes Care. 2019 Jun;42(6):1075-1080. doi: 10.2337/dc18-2028. Epub 2019 Apr 22.

PMID:
31010875
7.

An outcome model approach to transporting a randomized controlled trial results to a target population.

Goldstein BA, Phelan M, Pagidipati NJ, Holman RR, Pencina MJ, Stuart EA.

J Am Med Inform Assoc. 2019 May 1;26(5):429-437. doi: 10.1093/jamia/ocy188.

PMID:
30869798
8.

Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017.

Dennis JM, Henley WE, McGovern AP, Farmer AJ, Sattar N, Holman RR, Pearson ER, Hattersley AT, Shields BM, Jones AG; MASTERMIND consortium.

Diabetes Obes Metab. 2019 Jul;21(7):1576-1584. doi: 10.1111/dom.13687. Epub 2019 Apr 4.

9.

Progression of glucose-lowering diabetes therapy in TECOS.

Bethel MA, Engel SS, Stevens SR, Lokhnygina Y, Ding J, Josse RG, Alvarsson M, Hramiak I, Green JB, Peterson ED, Holman RR; TECOS Study Group.

Endocrinol Diabetes Metab. 2018 Dec 22;2(1):e00053. doi: 10.1002/edm2.53. eCollection 2019 Jan.

10.

Real-world studies no substitute for RCTs in establishing efficacy.

Gerstein HC, McMurray J, Holman RR.

Lancet. 2019 Jan 19;393(10168):210-211. doi: 10.1016/S0140-6736(18)32840-X. No abstract available.

PMID:
30663582
11.

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.

Fanaroff AC, Clare R, Pieper KS, Mahaffey KW, Melloni C, Green JB, Alexander JH, Jones WS, Harrison RW, Mehta RH, Povsic TJ, Moreira HG, Al-Khatib SM, Roe MT, Kong DF, Mathews R, Tricoci P, Holman RR, Wallentin L, Held C, Califf RM, Alexander KP, Lopes RD.

Circulation. 2019 Feb 12;139(7):863-873. doi: 10.1161/CIRCULATIONAHA.118.037202.

PMID:
30586739
12.

Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.

Mentz RJ, Thompson VP, Aguilar D, Choi J, Gustavson SM, Iqbal N, Kong AP, Öhman P, Sattar N, Scott RS, Wong YW, Holman RR, Hernandez AF.

Circulation. 2018 Nov 27;138(22):2576-2578. doi: 10.1161/CIRCULATIONAHA.118.036811. No abstract available.

PMID:
30571356
13.

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.

Clegg LE, Heerspink HJL, Penland RC, Tang W, Boulton DW, Bachina S, Fox RD, Fenici P, Thuresson M, Mentz RJ, Hernandez AF, Holman RR.

Diabetes Care. 2019 Feb;42(2):318-326. doi: 10.2337/dc18-1871. Epub 2018 Dec 6.

PMID:
30523029
14.

Diminutive Polyps With Advanced Histologic Features Do Not Increase Risk for Metachronous Advanced Colon Neoplasia.

Vleugels JLA, Hassan C, Senore C, Cassoni P, Baron JA, Rex DK, Ponugoti PL, Pellise M, Parejo S, Bessa X, Arnau-Collell C, Kaminski MF, Bugajski M, Wieszczy P, Kuipers EJ, Melson J, Ma KH, Holman R, Dekker E, Pohl H.

Gastroenterology. 2019 Feb;156(3):623-634.e3. doi: 10.1053/j.gastro.2018.10.050. Epub 2018 Nov 2.

PMID:
30395813
15.

Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.

Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felício JS, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD, Maggioni AP, Öhman P, Pagidipati NJ, Poulter NR, Ramachandran A, Reicher B, Holman RR, Hernandez AF; EXSCEL Study Group.

J Am Heart Assoc. 2018 Oct 2;7(19):e009304. doi: 10.1161/JAHA.118.009304.

16.

Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates.

Mostafa SA, Coleman RL, Agbaje OF, Gray AM, Holman RR, Bethel MA.

J Diabetes Complications. 2019 Jan;33(1):69-74. doi: 10.1016/j.jdiacomp.2018.09.017. Epub 2018 Oct 10.

PMID:
30361000
18.

Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial.

Kraus WE, Yates T, Tuomilehto J, Sun JL, Thomas L, McMurray JJV, Bethel MA, Holman RR.

BMJ Open Diabetes Res Care. 2018 Jul 19;6(1):e000523. doi: 10.1136/bmjdrc-2018-000523. eCollection 2018.

19.

Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.

Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT; MASTERMIND Consortium.

Diabetes Care. 2018 Sep;41(9):1844-1853. doi: 10.2337/dc18-0344. Epub 2018 Aug 2.

20.

National Quality Program Achieves Improvements in Safety Culture and Reduction in Preventable Harms in Community Hospitals.

Frush K, Chamness C, Olson B, Hyde S, Nordlund C, Phillips H, Holman R.

Jt Comm J Qual Patient Saf. 2018 Jul;44(7):389-400. doi: 10.1016/j.jcjq.2018.04.008. Epub 2018 Jun 6.

PMID:
30008351
21.

Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes.

Harrison P, Bethel MA, Kennedy I, Dinsdale R, Coleman R, Holman RR.

Platelets. 2019;30(4):521-529. doi: 10.1080/09537104.2018.1478402. Epub 2018 Jul 9.

PMID:
29985735
22.

Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.

Alfredsson J, Green JB, Stevens SR, Reed SD, Armstrong PW, Angelyn Bethel M, Engel SS, McGuire DK, Van de Werf F, Hramiak I, White HD, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2018 Oct;20(10):2379-2388. doi: 10.1111/dom.13377. Epub 2018 Jun 19.

PMID:
29923323
23.

Rabies Antibody Response After Booster Immunization: A Systematic Review and Meta-analysis.

Langedijk AC, De Pijper CA, Spijker R, Holman R, Grobusch MP, Stijnis C.

Clin Infect Dis. 2018 Nov 28;67(12):1932-1947. doi: 10.1093/cid/ciy420.

PMID:
29788204
24.

Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis.

Lim LL, Lau ESH, Kong APS, Davies MJ, Levitt NS, Eliasson B, Aguilar-Salinas CA, Ning G, Seino Y, So WY, McGill M, Ogle GD, Orchard TJ, Clarke P, Holman RR, Gregg EW, Gagliardino JJ, Chan JCN.

Diabetes Care. 2018 Jun;41(6):1312-1320. doi: 10.2337/dc17-2010. Review.

25.

A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks.

Riddle MC, Gerstein HC, Holman RR, Inzucchi SE, Zinman B, Zoungas S, Cefalu WT.

Diabetes Care. 2018 Jun;41(6):1121-1124. doi: 10.2337/dci18-0018. No abstract available.

PMID:
29784695
26.

Self-represented witnessing: the use of social media by asylum seekers in Australia's offshore immigration detention centres.

Rae M, Holman R, Nethery A.

Media Cult Soc. 2018 May;40(4):479-495. doi: 10.1177/0163443717746229. Epub 2017 Dec 12.

27.

What does the Acarbose Cardiovascular Evaluation (ACE) trial tell us?

Holman RR.

J Diabetes. 2018 Aug;10(8):683-685. doi: 10.1111/1753-0407.12770. Epub 2018 May 17. No abstract available.

PMID:
29774661
28.

Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.

Theodorakis MJ, Coleman RL, Feng H, Chan J, Chiasson JL, Ge J, Gerstein HC, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Tendera M, Tuomilehto J, Yang W, Hu D, Pan C, Holman RR; ACE Study Group.

Am Heart J. 2018 May;199:170-175. doi: 10.1016/j.ahj.2017.09.001. Epub 2017 Sep 8. No abstract available.

PMID:
29754657
29.

Analysis of clinical data to determine the minimum number of sensors required for adequate skin temperature monitoring of superficial hyperthermia treatments.

Bakker A, Holman R, Rodrigues DB, Dobšíček Trefná H, Stauffer PR, van Tienhoven G, Rasch CRN, Crezee H.

Int J Hyperthermia. 2018 Nov;34(7):910-917. doi: 10.1080/02656736.2018.1466000. Epub 2018 Apr 27.

PMID:
29658357
30.

Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT.

Griffin SJ, Bethel MA, Holman RR, Khunti K, Wareham N, Brierley G, Davies M, Dymond A, Eichenberger R, Evans P, Gray A, Greaves C, Harrington K, Hitman G, Irving G, Lessels S, Millward A, Petrie JR, Rutter M, Sampson M, Sattar N, Sharp S.

Health Technol Assess. 2018 Apr;22(18):1-64. doi: 10.3310/hta22180.

31.

Wyburn-Mason Syndrome.

So JM, Holman RE.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Feb 18.

32.

Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Reed SD, Li Y, Leal J, Radican L, Adler AI, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2018 Jul;20(7):1732-1739. doi: 10.1111/dom.13292. Epub 2018 Apr 20.

PMID:
29573215
33.

Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study): statistical analysis plan.

Onland W, Merkus MP, Nuytemans DH, Jansen-van der Weide MC, Holman R, van Kaam AH; SToP-BPD study group.

Trials. 2018 Mar 9;19(1):178. doi: 10.1186/s13063-018-2505-y.

34.

Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Davis TME, Mulder H, Lokhnygina Y, Aschner P, Chuang LM, Raffo Grado CA, Standl E, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2018 Jun;20(6):1427-1434. doi: 10.1111/dom.13242. Epub 2018 Feb 28.

PMID:
29405540
35.

Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.

Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, Pearson ER, Hattersley AT, Jones AG; MASTERMIND Consortium.

Diabetes Care. 2018 Apr;41(4):705-712. doi: 10.2337/dc17-1827. Epub 2018 Jan 31.

36.

Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.

Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JCN, Green JB, Lachin JM, Scheen A, Travert F, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2018 Mar;41(3):596-603. doi: 10.2337/dc17-1778. Epub 2018 Jan 8.

PMID:
29311155
37.

Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials.

Holman RR.

Nat Rev Endocrinol. 2018 Feb;14(2):67-68. doi: 10.1038/nrendo.2017.179. Epub 2018 Jan 5. Review. No abstract available.

PMID:
29302077
38.

Potential roles of inorganic phosphate on the progression of initially bound glucopyranose toward the nonenzymatic glycation of human hemoglobin: mechanistic diversity and impacts on site selectivity.

Smith BA, Mottishaw CR, Hendricks AJ, Mitchell J, Becker S, Ropski PS, Park B, Finkbeiner-Caufield M, Garay-Nontol B, Holman RW, Rodnick KJ.

Cogent Biol. 2018;4. pii: 1425196. doi: 10.1080/23312025.2018.1425196. Epub 2018 Jan 10.

39.

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.

40.

Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.

Holman RR, Bethel MA, Hernandez AF.

N Engl J Med. 2017 Dec 21;377(25):2502. doi: 10.1056/NEJMc1714163. No abstract available.

PMID:
29262286
41.

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group.

Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6. Epub 2017 Dec 6.

42.

Dairy production practices and associated risks for bovine vaccinia exposure in cattle, Brazil.

Borges IA, McCollum AM, Mehal JM, Haberling D, Dutra LAL, Vieira FN, Andrade LAO, Kroon EG, Holman RC, Reynolds MG, Trindade GS.

New Microbes New Infect. 2017 Aug 16;20:43-50. doi: 10.1016/j.nmni.2017.08.004. eCollection 2017 Nov.

43.

Questions arising when NHS staff who refuse flu vaccine have to explain why.

Holman R.

BMJ. 2017 Nov 16;359:j5244. doi: 10.1136/bmj.j5244. No abstract available.

PMID:
29146628
44.

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease.

Mostafa SA, Coleman RL, Agbaje OF, Gray AM, Holman RR, Bethel MA.

Diabet Med. 2018 Jan;35(1):72-77. doi: 10.1111/dme.13533. Epub 2017 Nov 16.

PMID:
29057545
45.

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.

Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2017 Dec;40(12):1763-1770. doi: 10.2337/dc17-1091. Epub 2017 Oct 6.

PMID:
28986504
46.

Health selection into neighborhoods among patients enrolled in a clinical trial.

Arcaya MC, Coleman RL, Razak F, Alva ML, Holman RR.

Prev Med Rep. 2017 Jul 24;8:51-54. doi: 10.1016/j.pmedr.2017.07.003. eCollection 2017 Dec.

47.

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C; ACE Study Group.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7. Lancet Diabetes Endocrinol. 2019 May;7(5):e5.

PMID:
28917545
48.

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group.

N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.

49.

Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.

Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, Odden MC, Peralta CA, Cheung AK, Nadkarni GN, Coleman RL, Holman RR, Zanchetti A, Peters R, Beckett N, Staessen JA, Ix JH.

JAMA Intern Med. 2017 Oct 1;177(10):1498-1505. doi: 10.1001/jamainternmed.2017.4377. Review.

50.

Is patient length of stay associated with intensive care unit characteristics?

Verburg IWM, Holman R, Dongelmans D, de Jonge E, de Keizer NF.

J Crit Care. 2018 Feb;43:114-121. doi: 10.1016/j.jcrc.2017.08.014. Epub 2017 Aug 10.

PMID:
28865340

Supplemental Content

Loading ...
Support Center